TY - JOUR
T1 - Assessment of prosthetic vascular graft thrombogenicity using the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 in a dog model
AU - Scharn, Dirk M
AU - Oyen, Wim J G
AU - Klemm, Peter L
AU - Wijnen, Marc H W A
AU - vanderVliet, J Adam
PY - 2002/12
Y1 - 2002/12
N2 - INTRODUCTION: Prosthetic graft patency greatly depends on graft thrombogenicity. The concept of graft thrombogenicity is poorly understood and difficult to measure or quantify. In a study we tested the experimental radiopharmaceutical DMP444 and developed a suitable dog model. This agent is a radiolabelled ((99m)Technetium) glycoprotein IIb/IIIa receptor antagonist with a high affinity for activated platelets. It binds to platelets that are intimately involved in thrombus formation. The agent does not affect thrombocyte function, when used in a dose necessary for imaging. DMP444 does not require platelet harvesting and processing. Early imaging of thrombocyte aggregation sites such as vascular prostheses is possible within 4 hours after injection.MATERIAL AND METHODS: Adult Beagle dogs weighing 12-15 kg were used for the experiments. In 16 dogs a prosthetic patch was sewn onto the abdominal aorta (Bovine pericard: n=4, Dacron: n=6, Human Umbilical Vein: n=6). Imaging cycles after injection of (99m)Technetium-labelled DMP444 were performed on days 1, 7, 14 and 28 after surgery.RESULTS: We noticed differences in thrombus formation on the tested graft materials. The bovine pericard patches (n=4) showed a relatively high rate of thrombocyte aggregation. In the Dacron patches (n=6) aggregation was not seen. In 1 of 6 cases of human umbilical vein patches a measurable focal aggregation was recorded.CONCLUSION: The method outlined in this study is a relatively simple and reproducable method to visualize thrombocyte aggregation.
AB - INTRODUCTION: Prosthetic graft patency greatly depends on graft thrombogenicity. The concept of graft thrombogenicity is poorly understood and difficult to measure or quantify. In a study we tested the experimental radiopharmaceutical DMP444 and developed a suitable dog model. This agent is a radiolabelled ((99m)Technetium) glycoprotein IIb/IIIa receptor antagonist with a high affinity for activated platelets. It binds to platelets that are intimately involved in thrombus formation. The agent does not affect thrombocyte function, when used in a dose necessary for imaging. DMP444 does not require platelet harvesting and processing. Early imaging of thrombocyte aggregation sites such as vascular prostheses is possible within 4 hours after injection.MATERIAL AND METHODS: Adult Beagle dogs weighing 12-15 kg were used for the experiments. In 16 dogs a prosthetic patch was sewn onto the abdominal aorta (Bovine pericard: n=4, Dacron: n=6, Human Umbilical Vein: n=6). Imaging cycles after injection of (99m)Technetium-labelled DMP444 were performed on days 1, 7, 14 and 28 after surgery.RESULTS: We noticed differences in thrombus formation on the tested graft materials. The bovine pericard patches (n=4) showed a relatively high rate of thrombocyte aggregation. In the Dacron patches (n=6) aggregation was not seen. In 1 of 6 cases of human umbilical vein patches a measurable focal aggregation was recorded.CONCLUSION: The method outlined in this study is a relatively simple and reproducable method to visualize thrombocyte aggregation.
KW - Animals
KW - Aorta, Abdominal/surgery
KW - Aortic Valve Stenosis/diagnostic imaging
KW - Bioprosthesis/adverse effects
KW - Blood Vessel Prosthesis/adverse effects
KW - Blood Vessel Prosthesis Implantation
KW - Disease Models, Animal
KW - Dogs
KW - Graft Occlusion, Vascular/diagnostic imaging
KW - Materials Testing
KW - Oligopeptides
KW - Organotechnetium Compounds
KW - Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
KW - Radionuclide Imaging
KW - Radiopharmaceuticals
KW - Thrombosis/diagnostic imaging
UR - http://www.scopus.com/inward/record.url?scp=0036890640&partnerID=8YFLogxK
U2 - 10.1016/s0967-2109(02)00077-7
DO - 10.1016/s0967-2109(02)00077-7
M3 - Article
C2 - 12453688
SN - 0967-2109
VL - 10
SP - 566
EP - 569
JO - Cardiovascular surgery (London, England)
JF - Cardiovascular surgery (London, England)
IS - 6
ER -